CN108420828B

CN108420828B - Hemodialysis concentrate for improving residual renal function

Info

Publication number: CN108420828B
Application number: CN201810294098.4A
Authority: CN
Inventors: 张海悦; 魏滢; 孙景春; 李雪; 王姝; 韩峰; 韩永双; 翟硕
Original assignee: Jilin Fusheng Medical Device Co ltd
Current assignee: Jilin Fusheng Medical Device Co ltd
Priority date: 2018-03-30
Filing date: 2018-03-30
Publication date: 2020-12-29
Anticipated expiration: 2038-03-30
Also published as: CN108420828A

Abstract

The invention relates to a hemodialysis concentrate for improving residual renal function, which comprises the hemodialysis concentrate and a blood-activating and blood-stasis-removing medicament, wherein the blood-activating and blood-stasis-removing medicament is ligustrazine, vinpocetine or nimodipine. The hemodialysis concentrate can inhibit renal tubular atrophy and fibrous tissue hyperplasia, and promote reversal of waste nephrons; improving blood flow, increasing renal tubular excretion rate and fibrin solution; improve the blood flow of arteriovenous internal fistula, protect the life line of a dialysis patient and improve the residual renal function of the dialysis patient. During each dialysis treatment period, the medicine can be directly dispersed from the dialysate area of the dialyzer to the blood area, so as to play the roles of resisting platelet aggregation and reducing blood viscosity of the blood area, so that the hollow fibers and the micropores of the dialysis membrane of the dialyzer are not easy to block, the dialysis effective area and the micropores of the dialysis membrane are kept smooth, and the metabolic wastes in the blood area are fully dialyzed and removed. It has effects in dilating arteriole, improving microcirculation and renal function, and protecting and improving residual nephron.

Description

Hemodialysis concentrate for improving residual renal function

Technical Field

The invention relates to a hemodialysis concentrate, in particular to a hemodialysis concentrate for improving residual renal function.

Background

Residual renal function refers to the filtration and endocrine function of kidney tissue after kidney tissue destruction. In general, the body can also excrete and degrade certain small molecules and produce certain amounts of erythropoietin and active vitamin D, as long as there is little residual renal function₃。

Hemodialysis is currently the primary treatment for uremia. However, the slow or acute irresistible loss of residual renal function of hemodialysis patients exists, and some patients who receive a plurality of times or even one time of hemodialysis can cause the rapid loss of residual renal function, so that the patients lose the value of traditional Chinese medicine treatment and have to rely completely on dialysis or kidney transplantation, which is one of the important reasons for refusing to receive hemodialysis of many patients. Therefore, under the condition of hemodialysis, the method protects the residual renal function and prevents the residual renal function from being lost quickly, and has very important significance for ensuring the sufficiency of dialysis, improving the living quality and survival rate of patients, reducing the occurrence of dialysis complications and reducing the dialysis time to save the treatment cost.

The Chinese medicine considers that: the pathogenesis of chronic renal failure is mainly the decline of spleen and kidney and the accumulation of damp-turbidity and blood stasis. Therefore, activating blood and resolving stasis is one of the main therapeutic methods of chronic renal failure. Relevant researches show that the medicine for promoting blood circulation and removing blood stasis can inhibit renal tubular atrophy and fibrous tissue hyperplasia and promote the reversion of the waste nephrons; improving blood flow, increasing renal tubular excretion rate, and increasing fibrin solution; improving circulation, regulating metabolism, immunity, and nervous system, and promoting tissue repair and regeneration.

Currently, conventional hemodialysis concentrates include both forms of hemodialysis concentrate and dry powder concentrate. Regardless of the formula of the hemodialysis concentrate, the type of the dialysis machine and the imbibing proportion, the concentration of various ions in the dialysate finally used for patients needs to be designed according to the blood components of human bodies and meets the treatment requirements. According to the regulation of the standard operating procedures for blood purification, the components and the concentration of the bicarbonate dialysate are 135-145 mmoL/L of sodium, 0-4 mmoL/L of potassium, 1.25-1.75 mmoL/L of calcium, 0.5-0.75 mmoL/L of magnesium, 100-115 mmoL/L of chlorine, 30-40 mmoL/L of bicarbonate and the like. For example, it is a new attempt to develop a hemodialysis concentrate for improving residual renal function by promoting blood circulation to remove blood stasis, which is very important for protecting residual renal function of dialysis patients.

Disclosure of Invention

The object of the present invention is to provide a hemodialysis concentrate for improving residual renal function, which protects residual renal function of dialysis patients from the viewpoint of promoting blood circulation to remove blood stasis.

The purpose of the invention is realized by the following technical scheme:

a hemodialysis concentrate for improving residual renal function comprises an acidic concentrate (component A) and a basic concentrate (component B), and further comprises a blood circulation promoting and blood stasis removing medicine added into the component A or the component B, wherein the blood circulation promoting and blood stasis removing medicine is ligustrazine, vinpocetine or nimodipine, the ligustrazine is added into the component A, the vinpocetine or the nimodipine is added into the component B, but the blood circulation promoting and blood stasis removing medicine cannot be added into the component A and the component B at the same time, so that the mutual reaction among medicines is avoided, and the medicine effect, the side effect and the medicine excess are reduced.

When ligustrazine is added to component a, the component a consists of an acidic concentrate of: 1023-1136 g of sodium chloride, 0-55 g of potassium chloride, 32-47 g of calcium chloride, 9-28 g of magnesium chloride, 21-132 g of pH regulator and 120-240 mg of ligustrazine; the component B consists of an alkaline concentrate of the following components: 566-960 g of sodium bicarbonate and 0-345 g of sodium chloride.

When vinpocetine or nimodipine is added to component B, the component a consists of an acidic concentrate of: 1023-1136 g of sodium chloride, 0-55 g of potassium chloride, 32-47 g of calcium chloride, 9-28 g of magnesium chloride and 21-132 g of pH regulator; the component B consists of an alkaline concentrate of the following components: 566-960 g of sodium bicarbonate, 0-345 g of sodium chloride and 80-200 mg of vinpocetine or nimodipine.

The pH regulator is acetic acid, citric acid, lactic acid, malic acid or amino acid.

Preferably, when ligustrazine is added to the a component, the amount of ligustrazine is 180 mg.

Preferably, the amount of vinpocetine when added to component B is 150 mg.

Preferably, when nimodipine is added to the B-component, the amount of nimodipine is 120 mg.

Of vinpocetine and nimodipine, vinpocetine is preferably added to the B component.

At present, ligustrazine is mainly used in the fields of occlusive vascular diseases, cerebral thrombosis, vasculitis, coronary heart disease, angina pectoris and the like. Through a large number of experiments, ligustrazine can improve the hyperglycemia state of a patient, increase the renal blood flow and improve the renal microcirculation. Nephrotic syndrome is caused by a decrease in plasma colloid osmotic pressure and a large amount of water exuded from plasma due to loss of a large amount of plasma protein, resulting in blood concentration. Ligustrazine inhibits platelet aggregation, dilates arterioles, improves microcirculation and cerebral blood flow, and also reduces whole blood viscosity. The compatibility of ligustrazine and hemodialysis solution is helpful for delaying the deterioration of chronic renal failure and improving the residual renal function of patients, and as the ligustrazine monomer is an alkaloid, the ligustrazine monomer exists in the form of salt at present, such as ligustrazine hydrochloride and ligustrazine phosphate, the pH values are acidic, and the ligustrazine is added into an acidic concentrate. Vinpocetine is a strong free radical scavenger, can enhance the activity of antioxidase and improve microcirculation, and the like, so that erythrocytes can pass through tiny blood vessels, reduce the viscosity of blood, inhibit the aggregation of platelets, enhance the deformability of the erythrocytes, and enable the erythrocytes to pass through the tiny blood vessels, reduce the viscosity of the blood, thereby preventing renal tubules from being further hardened. Nimodipine has the functions of expanding blood vessels and improving blood microcirculation, thereby being beneficial to delaying the deterioration of chronic renal failure and improving residual renal functions of patients.

Generally, most of the medicines for promoting blood circulation and removing blood stasis are Chinese patent medicines or Chinese herbal medicines, and the Chinese traditional medicines have complex components and large molecular weight, and after a large number of animal tests and medication monitoring of patients, the three medicines of ligustrazine, vinpocetine and nimodipine with proper doses are found to be suitable for being compatible with hemodialysis concentrates, enter the bodies of the patients through dialyzers to achieve the treatment effect, obviously improve the residual renal functions of the patients, and find the optimal addition dose through a large number of experiments.

Compared with the prior art, the invention has the beneficial effects that:

the hemodialysis concentrate of the invention can inhibit renal tubular atrophy and fibrous tissue hyperplasia and promote the reversion of waste nephrons; improving blood flow, increasing renal tubular excretion rate, and increasing fibrin solution; improve the blood flow of arteriovenous internal fistula, protect the life line of a dialysis patient and improve the residual renal function of the dialysis patient. During each dialysis treatment period, the medicine can be directly dispersed from the dialysate area of the dialyzer to the blood area, so that the effects of resisting platelet aggregation and reducing blood viscosity of the blood area are exerted, the hollow fibers and the micropores of the dialysis membrane of the dialyzer are not easy to block, the dialysis effective area and the micropores of the dialysis membrane are kept smooth, and the metabolic wastes in the blood area are fully dialyzed and removed. It has effects in dilating arteriole, improving microcirculation and renal function, and protecting and improving residual nephron.

Detailed Description

The hemodialysis concentrate for improving residual renal function of the invention is used for inputting a medicine for promoting blood circulation and removing blood stasis into a patient body in a dialysis way, and ligustrazine is taken as an example, and the rest are not listed.

The technical scheme of the embodiment of the invention is that the hemodialysis concentrate is compatible with the blood-activating and stasis-removing medicine so as to improve the residual renal function of a dialysis patient. The hemodialysis concentrate can be provided in a water agent mode and a powder mode, and if the hemodialysis concentrate is powder, dialysis water is required to be prepared into a concentrated solution according to instructions before use.

For comparison, three groups of examples are listed in which the hemodialysis concentrate is not added with the blood circulation promoting and blood stasis removing drug (general dialysate group), as shown in Table 1.

Example 1

A hemodialysis concentrate for improving residual renal function, comprising an A-component and a B-component, the A-component consisting of: 1023-1124 g of sodium chloride, 0-52 g of potassium chloride, 32-45 g of calcium chloride, 9-26 g of magnesium chloride and 21-90 g of pH regulator; the component B comprises the following components: 714-960 g of sodium bicarbonate.

The A component and the B component are respectively prepared into A concentrated solution and B concentrated solution by using 5L and 10L dialysis water.

Example 2

A hemodialysis concentrate for improving residual renal function, comprising an A-component and a B-component, the A-component consisting of: 1032-1136 g of sodium chloride, 0-52 g of potassium chloride, 32-45 g of calcium chloride, 9-26 g of magnesium chloride and 98-132 g of pH regulator; the component B comprises the following components: 714-960 g of sodium bicarbonate.

Example 3

A hemodialysis concentrate for improving residual renal function, comprising an A-component and a B-component, the A-component consisting of: 743-798 g of sodium chloride, 0-55 g of potassium chloride, 34-47 g of calcium chloride, 9-28 g of magnesium chloride and 22-88 g of pH regulator; the component B comprises the following components: 566-754 g of sodium bicarbonate and 262-345 g of sodium chloride.

TABLE 1 common dialysate groups

Example 4

A hemodialysis concentrate for improving residual renal function, comprising an A-component and a B-component, the A-component consisting of: 1054g of sodium chloride, 26g of potassium chloride, 32g of calcium chloride, 18g of magnesium chloride, 47g of pH regulator and 0.12g of ligustrazine; the component B comprises the following components: 840g of sodium bicarbonate.

Example 5

A hemodialysis concentrate for improving residual renal function, comprising an A-component and a B-component, the A-component consisting of: 1054g of sodium chloride, 26g of potassium chloride, 39g of calcium chloride, 18g of magnesium chloride, 47g of pH regulator and 0.18g of ligustrazine; the component B comprises the following components: 840g of sodium bicarbonate.

Example 6

A hemodialysis concentrate for improving residual renal function, comprising an A-component and a B-component, the A-component consisting of: 1054g of sodium chloride, 26g of potassium chloride, 45g of calcium chloride, 18g of magnesium chloride, 47g of pH regulator and 0.24g of ligustrazine; the component B comprises the following components: 840g of sodium bicarbonate.

Example 7

A hemodialysis concentrate for improving residual renal function, comprising an A-component and a B-component, the A-component consisting of: 1069g of sodium chloride, 26g of potassium chloride, 45g of calcium chloride, 18g of magnesium chloride, 132g of pH regulator and 0.18g of ligustrazine; the component B comprises the following components: 697g of sodium bicarbonate.

Example 8

A hemodialysis concentrate for improving residual renal function, comprising an A-component and a B-component, the A-component consisting of: 807g of sodium chloride, 28g of potassium chloride, 41g of calcium chloride, 19g of magnesium chloride, 55g of pH regulator and 0.24g of ligustrazine; the component B comprises the following components: 660g of sodium bicarbonate and 306g of sodium chloride.

Inventive examples 4-8 are shown in table 2. The ligustrazine is required to be used according to the condition of a patient and the advice of a doctor during each dialysis, and the dosage range of the ligustrazine is 24-48 mg/L.

Table 2 inventive examples 4-8

The test method comprises the following steps:

a500 mL disinfection bottle is tightly connected with an arterial end of a dialysis pipeline through a soft rubber tube, physiological saline replaces blood to carry out extracorporeal circulation hemodialysis, the flow of the physiological saline is 200mL/min, the flow of dialysate is 500mL/min, the ultrafiltration amount is 0.3kg/h, the type of a dialyzer is Beran LO15, and the content of ligustrazine added into the dialysate is 24-48 mg/L. After dialysis for 4 hours, the content of ligustrazine in the dialyzed blood and the dialyzate was measured by high performance liquid chromatography.

Example 9

(1) Before dialysis:

blood side: physiological saline;

dialysate side: the composition of the dialysis concentrate is given in example 4 and is measured as a: b: after dilution with water at 1:1.225:32.775, the ion concentration in the dialysate is shown in table 3:

table 3 ion concentration and pH of the diluted dialysate of example 4

(2) After dialysis:

the ligustrazine content in the dialyzed blood and the dialyzate was measured by high performance liquid chromatography, and the results are shown in Table 4.

Table 4 unit of ligustrazine content in the dialyzed blood and dialysate side: mmoL/L

Sample (I)	Test 1	Test 2	Test 3	Test 4	Test 5	Average
							Physiological saline	0.0125	0.0124	0.0123	0.0125	0.0124	0.0124
Dialysis liquid	0.0126	0.0127	0.0125	0.0124	0.0126	0.0126

Example 10

(1) Before dialysis:

blood side: physiological saline;

dialysate side: the composition of the dialysis concentrate is given in example 5 and is measured as a: b: after dilution with water at 1:1.225:32.775, the ion concentration in the dialysate is shown in table 5:

table 5 ion concentration and pH of the diluted dialysate of example 5

(2) After dialysis:

the ligustrazine content in the dialyzed blood and the dialyzate was measured by high performance liquid chromatography, and the results are shown in Table 6.

Table 6 unit of ligustrazine content in the dialyzed blood and dialysate side: mmoL/L

Sample (I)	Test 1	Test 2	Test 3	Test 4	Test 5	Average
							Physiological saline	0.0188	0.0186	0.0186	0.0185	0.0187	0.0186
Dialysis liquid	0.0187	0.0189	0.0189	0.0188	0.0187	0.0188

Example 11

(1) Before dialysis:

blood side: physiological saline;

dialysate side: the composition of the dialysis concentrate is given in example 8 and is measured as a: b: after dilution with water at 1:1.83:34, the ion concentration in the dialysate is shown in table 7:

table 7 ion concentration and pH of the diluted dialysate of example 8

(2) After dialysis:

the ligustrazine content in the dialyzed blood and the dialyzate was measured by high performance liquid chromatography, and the results are shown in Table 8.

Table 8 unit of ligustrazine content in the dialyzed blood and dialysate side: mmoL/L

Sample (I)	Test 1	Test 2	Test 3	Test 4	Test 5	Average
							Physiological saline	0.0241	0.0262	0.0254	0.0247	0.0245	0.0250
Dialysis liquid	0.0242	0.0255	0.0265	0.0247	0.0253	0.0252

The data in examples 9, 10, 11 show that:

before dialysis, a certain amount of ligustrazine is added into the dialysate, after dialysis, the content of ligustrazine in the physiological saline and the dialysate is changed before and after dialysis, the content of ligustrazine in the dialysate is reduced, the content of ligustrazine in the physiological saline is increased, the content of two sides is basically equal to half of the content before dialysis, and the result shows that the ligustrazine can enter the physiological saline (blood) through a dialyzer in the dialysis process, the expected treatment effect is achieved, and the living quality of a patient is further ensured.

Example 12

The ligustrazine dialysate and the common dialysate of the invention are respectively used for dialysis treatment of dialysis patients, and the influences of SCR, BUN and electrolytes on the blood of the patients are evaluated. The method comprises the following steps:

the mean age of the ligustrazine dialysate group 1 (treatment group 1) and 20 dialysis patients, including 12 men and 8 women, was 45.3 years old (20-70 years old), and the mean values of Serum Creatinine (SCR) and urea nitrogen (BUN) before treatment were 1131. mu. mol/L and 36.7mmol/L, respectively; adding 24mg/L ligustrazine into the hemodialysis concentrate A.

In the ligustrazine dialysate group 2 (treatment group 2), among 20 dialysis patients, 11 men and 9 women have an average age of 46.1 years (21-71 years), and the average values of blood creatinine (SCR) and urea nitrogen (BUN) before treatment are 1143 mu mol/L and 34.9mmol/L respectively; adding ligustrazine 36mg/L into the hemodialysis concentrate A.

In the ligustrazine dialysate group 3 (treatment group 3), of 20 dialysis patients, 12 men and 8 women have an average age of 45.7 years (23-69 years), and the average values of blood creatinine (SCR) and urea nitrogen (BUN) before treatment are 1151. mu. mol/L and 33.4mmol/L respectively; adding 48mg/L ligustrazine into the hemodialysis concentrate A.

In the general dialysate group (control group), among 20 dialysis patients, 14 men and 6 women had an average age of 42.3 years (23-72 years), and the mean values of Serum Creatinine (SCR) and urea nitrogen (BUN) before treatment were 1052. mu. mol/L and 30.7mmol/L, respectively.

The data of the treatment group 1, the treatment group 2, the treatment group 3 and the control group are about the same in the male and female proportion, age and renal function. The indexes of SCR, BUN, Na, K, Ca, Cl and P in blood before and after hemodialysis of two groups of dialysis patients are observed.

TABLE 9 Effect of treatment and control groups on SCR and BUN before and after dialysis for dialysis patients (X. + -. SD)

The above experimental data show that before dialysis, there is no significant difference (P > 0.05) in the mean values of SCR and BUN in the blood of patients in the treatment group 1, the treatment group 2, the treatment group 3 and the control group, and after dialysis, there is a very significant difference (P < 0.01) in the mean values of SCR and BUN in the blood of patients in the 3 treatment groups and the control group, and the clearance rates of creatinine and urea nitrogen in the blood of the 3 treatment groups are all higher than that of the control group, thus significantly improving the dialysis effect. Meanwhile, the data show that the larger the addition amount of the ligustrazine, the higher the clearance rate of the blood creatinine and the urea nitrogen is, but the clearance rates of the treatment group 2 and the treatment group 3 are not much different, namely, the influences on the clearance rates of the blood creatinine and the urea nitrogen are not much different and have no significant difference when the ligustrazine with the concentration of 36mg/L and 48mg/L is added.

TABLE 10 influence of the treatment and control groups on electrolytes before and after dialysis for dialysis patients (X. + -. SD)

As can be seen from the above test data, through the detection of Na, K, Ca, Cl and P in the sera of 3 patients dialyzed by the treatment group and the control group, the mean value comparison of the indexes of the treatment group 1 and the treatment group 2 compared with the control group is found to have no significant difference in statistics (P is more than 0.05); the serum Na, K, Ca and Cl in the treatment group 3 are not different, but the content of P is obviously different from that in the control group (P < 0.01). The above data indicate that the ligustrazine dialysate added with 24mg/L and 36mg/L is the same as the common dialysate in terms of electrolyte balance and does not cause electrolyte disturbance in the patient. The clearance rate of the added ligustrazine dialysate of 48mg/L to the serum P of the patient is higher than that of the control group, and a significant difference occurs, which is probably related to better effect of clearing SCR and BUN.

In conclusion, the clinical effect of adding 36mg/L ligustrazine dialysate is the best in the aspects of the clearance rate of SCR and BUN in blood of dialysis patients and the influence of each ion concentration in serum.

The ligustrazine molecules can be directly dispersed to a blood area from a dialyzate area of a dialyzer to play roles of resisting platelet aggregation and reducing blood viscosity of the blood area, so that hollow fibers and micropores of a dialysis membrane of the dialyzer are not easy to block, the dialysis effective area and the micropores of the dialysis membrane are kept smooth, and metabolic wastes in the blood area are fully dialyzed and removed. It has effects in dilating arteriole, improving microcirculation and renal function, protecting residual nephron, and improving function.

In addition, for a hemodialysis patient, the arteriovenous internal fistula is the most important vascular access for hemodialysis, and the formation of thrombus is one of the main reasons for insufficient blood flow of the arteriovenous internal fistula.

Example 13

The vinpocetine dialysate and the common dialysate are respectively used for dialysis treatment of dialysis patients, and the influences of SCR, BUN and electrolytes on blood of the patients are evaluated. The method comprises the following steps:

the vinpocetine dialysate group 1 (treatment group 1) comprises 20 dialysis patients, namely 9 men and 11 women, the average age is 46.3 years (21-67 years), and the average values of blood creatinine (SCR) and urea nitrogen (BUN) before treatment are 1145 mu mol/L and 35.6mmol/L respectively; to the hemodialysis concentrate B was added vinpocetine at 10 mg/L.

The vinpocetine dialysate group 2 (treatment group 2) comprises 20 dialysis patients, namely 11 men and 9 women, wherein the average age is 45.1 years (20-73 years), and the average values of blood creatinine (SCR) and urea nitrogen (BUN) before treatment are 1153 mu mol/L and 36.9mmol/L respectively; to the hemodialysis concentrate B was added vinpocetine at 15 mg/L.

The vinpocetine dialysate group 3 (treatment group 3) comprises 20 dialysis patients, namely 10 men and 10 women, the average age is 47.7 years (23-71 years), and the average values of blood creatinine (SCR) and urea nitrogen (BUN) before treatment are 1141 mu mol/L and 35.5mmol/L respectively; to the hemodialysis concentrate B was added vinpocetine at 20 mg/L.

In the general dialysate group (control group), among 20 dialysis patients, 14 men and 6 women had an average age of 42.3 years (23-72 years), and the mean values of Serum Creatinine (SCR) and urea nitrogen (BUN) before treatment were 1042. mu. mol/L and 33.7mmol/L, respectively.

TABLE 11 Effect of treatment and control groups on SCR and BUN before and after dialysis for dialysis patients (X. + -. SD)

The above experimental data show that before dialysis, there is no significant difference (P > 0.05) in the mean values of SCR and BUN in the blood of patients in the treatment group 1, the treatment group 2, the treatment group 3 and the control group, and after dialysis, there is a very significant difference (P < 0.01) in the mean values of SCR and BUN in the blood of patients in the 3 treatment groups and the control group, and the clearance rates of creatinine and urea nitrogen in the blood of the 3 treatment groups are all higher than that of the control group, thus significantly improving the dialysis effect. The data also show that greater amounts of vinpocetine added result in higher clearance of serum creatinine and urea nitrogen.

TABLE 12 influence of treatment and control groups on electrolytes before and after dialysis for dialysis patients (X + -SD)

The above experimental data show that, through the detection of the serum Na, K, Ca, Cl and P of the dialysis patients of the 3 treatment groups and the control group, the mean value comparison of the indexes of the 3 treatment groups has no statistically significant difference (P > 0.05) compared with the control group, and the above data indicate that the vinpocetine dialysate is the same as the common dialysate in terms of electrolyte balance and does not cause electrolyte disorder in the body of the patient.

However, after dialysis, 1 patient in treatment group 3 had headache and drowsiness, while the patients in treatment groups 1 and 2 did not respond to this. Whether this is related to an excessive amount of vinpocetine added is not clear, so for safety reasons the optimum amount of vinpocetine added should be 15 mg/L.

Example 14

The nimodipine dialysate and the common dialysate are respectively used for carrying out dialysis treatment on dialysis patients, and the influences of SCR, BUN and electrolytes on the blood of the patients are evaluated. The method comprises the following steps:

nimodipine dialysate group 1 (treatment group 1), 20 dialysis patients, 8 men and 12 women, mean age 45.3 years (18-71 years), mean values of blood creatinine (SCR) and urea nitrogen (BUN) before treatment are 1058 μmol/L and 37.6mmol/L respectively; nimodipine 8mg/L was added to the hemodialysis concentrate B.

Nimodipine dialysate group 2 (treatment group 2), dialysis patients 20, 9 men and 11 women, mean age 47.1 (24-75 years), blood creatinine (SCR) and urea nitrogen (BUN) mean values before treatment were 1064 μmol/L and 35.6mmol/L, respectively; nimodipine at 12mg/L was added to the hemodialysis concentrate B.

Nimodipine dialysate group 3 (treatment group 3), 20 dialysis patients, 12 men and 8 women, with average age of 46.7 years (21-75 years), and blood creatinine (SCR) and urea nitrogen (BUN) before treatment mean values of 1073 μmol/L and 37.5mmol/L, respectively; at hemodialysis concentrate B, 16mg/L nimodipine was added.

In the general dialysate group (control group), 20 dialysis patients, 12 men and 8 women, with the average age of 44.3 years (21-72 years), had mean values of blood creatinine (SCR) and urea nitrogen (BUN) of 1021. mu. mol/L and 36.7mmol/L, respectively, before treatment.

TABLE 13 Effect of treatment and control groups on SCR and BUN before and after dialysis for dialysis patients (X. + -. SD)

The above experimental data show that before dialysis, there is no significant difference (P > 0.05) in the mean values of SCR and BUN in the blood of the patients in the treatment group 1, the treatment group 2, the treatment group 3 and the control group, and after dialysis, there is a very significant difference (P < 0.01) in the mean values of SCR and BUN in the blood of the patients in the treatment group 2 and the control group 3 and the control group, and the difference is higher than the clearance rates of creatinine and urea nitrogen in the blood of the control group, so that the dialysis effect is significantly improved. However, the clearance of serum SCR in the treatment group 1 was less significant (P > 0.05) than the control group, indicating that the dose of nimodipine 8mg/L may be less and the treatment effect is not good.

TABLE 14 Effect of treatment and control groups on electrolytes before and after dialysis for dialysis patients (X + -SD)

The above experimental data show that, through the detection of the serum Na, K, Ca, Cl and P of the dialysis patients of the 3 treatment groups and the control group, the mean value comparison of the indexes of the 3 treatment groups has no statistically significant difference (P > 0.05) compared with the control group, and the above data indicate that the nimodipine dialysate is the same as the common dialysate in terms of electrolyte balance and does not cause electrolyte disorder in the body of the patient.

However, after dialysis, 3 patients in treatment group 3 fed back dizziness and hyperhidrosis, whereas patients in treatment groups 1 and 2 did not respond to this. Whether or not this is associated with an excessive amount of nimodipine is unknown, so the optimum amount of nimodipine should be 12 mg/L.

In conclusion, it can be seen that the addition of a certain amount of vinpocetine and nimodipine to the hemodialysis concentrate B can improve the clearance rate of serum creatinine and urea nitrogen, and does not cause ion disorder to the body of a patient, but the test result shows that the addition of nimodipine has more side effects than the addition of vinpocetine dialysate, so that the addition of vinpocetine to the hemodialysis concentrate B is superior to nimodipine.

The hemodialysis concentrate can inhibit renal tubular atrophy and fibrous tissue hyperplasia and promote the reversion of waste nephrons; improving blood flow, increasing renal tubular excretion rate, and increasing fibrin solution; improve the blood flow of arteriovenous internal fistula, protect the life line of a dialysis patient and improve the residual renal function of the dialysis patient.

The embodiments of the present invention and the experiments related to the embodiments have been described in detail above, but the above description is only a preferred embodiment of the present invention and should not be construed as limiting the scope of the present invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.

Claims

1. A hemodialysis concentrate for improving residual renal function, comprising a component A and a component B, wherein: 180mg of ligustrazine is also added into the component A; the A component consists of an acidic concentrate of the following components: 1023-1136 g of sodium chloride, 0-55 g of potassium chloride, 32-47 g of calcium chloride, 9-28 g of magnesium chloride and 21-132 g of pH regulator; the component B consists of an alkaline concentrate of the following components: 566-960 g of sodium bicarbonate and 0-345 g of sodium chloride.

2. A hemodialysis concentrate for improving residual renal function according to claim 1, wherein: the pH regulator is acetic acid, citric acid, lactic acid, malic acid or amino acid.

3. A hemodialysis concentrate for improving residual renal function, comprising a component A and a component B, wherein: 150mg of vinpocetine or 120mg of nimodipine is also added into the component B; the A component consists of an acidic concentrate of the following components: 1023-1136 g of sodium chloride, 0-55 g of potassium chloride, 32-47 g of calcium chloride, 9-28 g of magnesium chloride and 21-132 g of pH regulator; the component B consists of an alkaline concentrate of the following components: 566-960 g of sodium bicarbonate and 0-345 g of sodium chloride.

4. A hemodialysis concentrate for improving residual renal function according to claim 3, wherein: the pH regulator is acetic acid, citric acid, lactic acid, malic acid or amino acid.

5. A hemodialysis concentrate for improving residual renal function according to claim 3, wherein: the component B is added with vinpocetine.